Comparative Pharmacology
Head-to-head clinical analysis: THYQUIDITY versus THYROLAR 3.
Peer-Reviewed Evidence
Head-to-head clinical analysis: THYQUIDITY versus THYROLAR 3.
THYQUIDITY vs THYROLAR-3
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Thyroid hormone replacement; levothyroxine (T4) is deiodinated to triiodothyronine (T3), which binds to thyroid hormone receptors, regulating gene transcription and increasing metabolic rate.
THYROLAR-3 is a combination of synthetic T4 (levothyroxine) and T3 (liothyronine) that replaces or supplements endogenous thyroid hormones. T4 is converted to the active T3 in peripheral tissues. Thyroid hormones bind to thyroid hormone receptors (TRα and TRβ), regulating gene transcription involved in metabolism, growth, and development.
50 mg orally once daily, with or without food.
Adults: Initial dose 30 mg orally once daily; adjust based on thyroid function tests. Typical maintenance dose 60-120 mg once daily.
None Documented
None Documented
The terminal elimination half-life of levothyroxine is approximately 6-7 days in euthyroid individuals. In hyperthyroidism, half-life decreases to 3-4 days; in hypothyroidism, it can extend to 9-10 days. This long half-life supports once-daily dosing and allows for steady-state achievement in about 6-8 weeks.
Levothyroxine (T4): 6-7 days; Liothyronine (T3): 1-2 days. Clinical context: In hyperthyroidism, half-life shortened; in hypothyroidism, prolonged.
Thyquidity (levothyroxine sodium) is primarily excreted via the kidneys as unchanged drug and metabolites. Approximately 20-40% of an oral dose is excreted in feces via biliary elimination, with the remainder eliminated renally. Up to 80% of an administered dose appears in urine as thyroxine and its metabolites, primarily glucuronide and sulfate conjugates.
Renal (approximately 50% as unchanged drug and conjugates); fecal (~20%); biliary (~10%)
Category C
Category C
Thyroid Hormone
Thyroid Hormone